Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Imatinib mesylate was initially approved for chronic myeloid leukemia. It has also been used against gastrointestinal cancer and melanoma. What are the implications of broadening the application of this targeted cancer drug for the way that cancers are diagnosed and classified, and what will the impact be on clinical trial design? Are we getting closer to the end of tumor-typing by location?
Imatinib mesylate was initially approved for chronic myeloid leukemia. It has also been used against gastrointestinal cancer and melanoma. What are the implications of broadening the application of this targeted cancer drug for the way that cancers are diagnosed and classified, and what will the impact be on clinical trial design? Are we getting closer to the end of tumor-typing by location?
IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue
IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis
Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies
Level Up Your Skills: Tailoring Management of HF
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
First-line Chemotherapy Options in Metastatic PDAC
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Stay current with the best on medical education
